The Clav Protocol
5-Layer Stack
Clavicular's complete peptide protocol — every compound, every mechanism, every layer documented.
GLP-3 R — Retatrutide
The most potent GLP compound in clinical research. Glucagon receptor agonism drives hepatic fat oxidation and thermogenesis — mechanisms absent in semaglutide or tirzepatide. Phase 2 data: −28.7% body weight at 48 weeks. The reason for the entire stack.
BPC-157
GLP-1 agonists slow gastric emptying and alter gut motility — nausea (43%), diarrhea (34%) in Phase 2. BPC-157's NO system upregulation maintains mucosal integrity throughout. Run from day 1, not as a reactive measure. Non-negotiable with Retatrutide.
GHK-CU — Copper Peptide
When you lose 28% body weight, your skin has to adapt. GHK-CU upregulates collagen synthesis, drives VEGF angiogenesis (the luminosity/GLOW mechanism), and activates Cu-SOD antioxidant defense. The aesthetic optimization layer. Clavicular calls it the GLOW protocol.
SNAP-8
SNAP-8 is a SNAP-25 N-terminal analog that competes for SNARE complex binding at the NMJ, partially inhibiting ACh release. Lower expression muscle contraction force → reduced dynamic wrinkle deepening. Preclinical models: up to 63% wrinkle depth reduction. The KLOW layer.
CJC-1295 / Ipamorelin (No DAC)
Aggressive GLP protocols can produce lean mass loss alongside fat loss. CJC-1295/Ipamorelin provides pulsatile GH elevation that supports lean tissue preservation. No DAC preserves natural GH pulsatility. No cortisol elevation — Ipamorelin is highly selective for GHS-R1a.
The Data
Why Not Semaglutide.
Why Not Tirzepatide.
Why Retatrutide.
The glucagon receptor addition drives hepatic beta-oxidation and brown adipose thermogenesis — mechanisms absent in semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). These are active fat-burning mechanisms, not just appetite suppression. The Phase 2 result of −28.7% at 48 weeks had not plateaued — Retatrutide is a different category.
GLP Weight Loss Data
Retatrutide Dose Escalation Reference
| Phase | Dose | Duration | Note |
|---|---|---|---|
| Initiation | 2mg/week | Weeks 1–4 | GI adaptation phase |
| Escalation 1 | 4mg/week | Weeks 5–8 | Tolerance checkpoint |
| Escalation 2 | 8mg/week | Weeks 9+ | Phase 2 max dose |
All dosing data drawn from published Phase 2 trial. For research reference only.
The Official Protocol. The Only Stack.
Build the Stack.
Run the Protocol.
Research-grade, HPLC verified, ships from the US. Apollo Peptide Sciences.
For research purposes only. Not intended for human use.